Effects of growth hormone treatment in children with Prader-Willi syndrome

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Short stature, decreased muscle mass (hypotonia), increased body fat, decreased bone mineral density and other somatic abnormalities are major causes of morbidity and social limitation in individuals with Prader-Willi syndrome. Detailed studies indicate that two major endocrine pathologies may account for many of these somatic abnormalities. A true deficiency of the growth hormone (GH)-insulin-like growth factor axis is a principal cause of the short stature and is probably a major contributor to the decreased muscle mass and osteopenia. Hypogonadotropic hypogonadism is the probable primary cause of osteopenia and osteoporosis. No other endocrine abnormalities have been specifically identified in Prader-Willi syndrome, although there may be increased risks of premature adrenarche and type 2 diabetes mellitus, both secondary to obesity. GH replacement therapy is effective in normalizing linear growth and also has positive effects on muscle mass and function, and on bone mineralization. Judicious gonadal steroid replacement may be effective in treating the osteopenia and preventing osteoporosis. GH and gonadal steroid replacement therapy should be considered for all patients with Prader-Willi syndrome. (C) 2000 Harcourt Publishers Ltd.

Original languageEnglish (US)
JournalGrowth Hormone and IGF Research
Volume10
Issue numberSUPPL. B
StatePublished - 2000
Externally publishedYes

Fingerprint

Prader-Willi Syndrome
Metabolic Bone Diseases
Growth Hormone
Osteoporosis
Adrenarche
Steroids
Physiologic Calcification
Muscles
Muscle Hypotonia
Hypogonadism
Hormone Replacement Therapy
Somatomedins
Bone Density
Type 2 Diabetes Mellitus
Adipose Tissue
Therapeutics
Obesity
Pathology
Morbidity
Growth

Keywords

  • Growth hormone
  • Growth hormone deficiency
  • Hypogonadism
  • Osteoporosis
  • Prader-Willi syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of growth hormone treatment in children with Prader-Willi syndrome. / Lee, Phillip.

In: Growth Hormone and IGF Research, Vol. 10, No. SUPPL. B, 2000.

Research output: Contribution to journalArticle

@article{06ac9f4c713d435f8b7f2137500f9e00,
title = "Effects of growth hormone treatment in children with Prader-Willi syndrome",
abstract = "Short stature, decreased muscle mass (hypotonia), increased body fat, decreased bone mineral density and other somatic abnormalities are major causes of morbidity and social limitation in individuals with Prader-Willi syndrome. Detailed studies indicate that two major endocrine pathologies may account for many of these somatic abnormalities. A true deficiency of the growth hormone (GH)-insulin-like growth factor axis is a principal cause of the short stature and is probably a major contributor to the decreased muscle mass and osteopenia. Hypogonadotropic hypogonadism is the probable primary cause of osteopenia and osteoporosis. No other endocrine abnormalities have been specifically identified in Prader-Willi syndrome, although there may be increased risks of premature adrenarche and type 2 diabetes mellitus, both secondary to obesity. GH replacement therapy is effective in normalizing linear growth and also has positive effects on muscle mass and function, and on bone mineralization. Judicious gonadal steroid replacement may be effective in treating the osteopenia and preventing osteoporosis. GH and gonadal steroid replacement therapy should be considered for all patients with Prader-Willi syndrome. (C) 2000 Harcourt Publishers Ltd.",
keywords = "Growth hormone, Growth hormone deficiency, Hypogonadism, Osteoporosis, Prader-Willi syndrome",
author = "Phillip Lee",
year = "2000",
language = "English (US)",
volume = "10",
journal = "Endocrinology and Metabolism",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "SUPPL. B",

}

TY - JOUR

T1 - Effects of growth hormone treatment in children with Prader-Willi syndrome

AU - Lee, Phillip

PY - 2000

Y1 - 2000

N2 - Short stature, decreased muscle mass (hypotonia), increased body fat, decreased bone mineral density and other somatic abnormalities are major causes of morbidity and social limitation in individuals with Prader-Willi syndrome. Detailed studies indicate that two major endocrine pathologies may account for many of these somatic abnormalities. A true deficiency of the growth hormone (GH)-insulin-like growth factor axis is a principal cause of the short stature and is probably a major contributor to the decreased muscle mass and osteopenia. Hypogonadotropic hypogonadism is the probable primary cause of osteopenia and osteoporosis. No other endocrine abnormalities have been specifically identified in Prader-Willi syndrome, although there may be increased risks of premature adrenarche and type 2 diabetes mellitus, both secondary to obesity. GH replacement therapy is effective in normalizing linear growth and also has positive effects on muscle mass and function, and on bone mineralization. Judicious gonadal steroid replacement may be effective in treating the osteopenia and preventing osteoporosis. GH and gonadal steroid replacement therapy should be considered for all patients with Prader-Willi syndrome. (C) 2000 Harcourt Publishers Ltd.

AB - Short stature, decreased muscle mass (hypotonia), increased body fat, decreased bone mineral density and other somatic abnormalities are major causes of morbidity and social limitation in individuals with Prader-Willi syndrome. Detailed studies indicate that two major endocrine pathologies may account for many of these somatic abnormalities. A true deficiency of the growth hormone (GH)-insulin-like growth factor axis is a principal cause of the short stature and is probably a major contributor to the decreased muscle mass and osteopenia. Hypogonadotropic hypogonadism is the probable primary cause of osteopenia and osteoporosis. No other endocrine abnormalities have been specifically identified in Prader-Willi syndrome, although there may be increased risks of premature adrenarche and type 2 diabetes mellitus, both secondary to obesity. GH replacement therapy is effective in normalizing linear growth and also has positive effects on muscle mass and function, and on bone mineralization. Judicious gonadal steroid replacement may be effective in treating the osteopenia and preventing osteoporosis. GH and gonadal steroid replacement therapy should be considered for all patients with Prader-Willi syndrome. (C) 2000 Harcourt Publishers Ltd.

KW - Growth hormone

KW - Growth hormone deficiency

KW - Hypogonadism

KW - Osteoporosis

KW - Prader-Willi syndrome

UR - http://www.scopus.com/inward/record.url?scp=0033900036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033900036&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 1096-6374

IS - SUPPL. B

ER -